RT Journal Article
SR Electronic
T1 Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.20.20157800
DO 10.1101/2020.07.20.20157800
A1 Ostkamp, Patrick
A1 Salmen, Anke
A1 Pignolet, Béatrice
A1 Görlich, Dennis
A1 Andlauer, Till F. M.
A1 Schulte-Mecklenbeck, Andreas
A1 Gonzalez-Escamilla, Gabriel
A1 Bucciarelli, Florence
A1 Gennero, Isabelle
A1 Breuer, Johanna
A1 Antony, Gisela
A1 Schneider-Hohendorf, Tilman
A1 Mykicki, Nadine
A1 Bayas, Antonios
A1 Bergh, Florian Then
A1 Bittner, Stefan
A1 Hartung, Hans-Peter
A1 Friese, Manuel A.
A1 Linker, Ralf A.
A1 Luessi, Felix
A1 Lehmann-Horn, Klaus
A1 Mühlau, Mark
A1 Paul, Friedemann
A1 Stangel, Martin
A1 Tackenberg, Björn
A1 Tumani, Hayrettin
A1 Warnke, Clemens
A1 Weber, Frank
A1 Wildemann, Brigitte
A1 Zettl, Uwe K.
A1 Ziemann, Ulf
A1 Müller-Myhsok, Bertram
A1 Kümpfel, Tania
A1 Klotz, Luisa
A1 Meuth, Sven G.
A1 Zipp, Frauke
A1 Hemmer, Bernhard
A1 Hohlfeld, Reinhard
A1 Brassat, David
A1 Gold, Ralf
A1 Gross, Catharina C.
A1 Lukas, Carsten
A1 Groppa, Sergiu
A1 Loser, Karin
A1 Wiendl, Heinz
A1 Schwab, Nicholas
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/07/26/2020.07.20.20157800.abstract
AB Background Multiple sclerosis (MS) disease risk is associated with reduced sun exposure. This study assessed the relationship between measures of sun-exposure (vitamin D (vitD), latitude) and MS disease severity, the mechanisms of action, and effect-modification by medication and sun-sensitivity associated MC1R variants.Methods Two multi-center cohort studies (nNationMS=946, nBIONAT=991). Outcomes were the multiple sclerosis severity score (MSSS) and the number of Gd-enhancing lesion (GELs). RNAseq of four immune cell populations before and after UV-phototherapy of five MS patients.Results High serum vitD was associated with reduced MSSS (PNationMS=0.021; PBIONAT=0.007) and reduced risk for disease aggravation (PNationMS=0.032). Low latitude was associated with higher vitD, lower MSSS (PNationMS=0.018), fewer GELs (PNationMS=0.030) and reduced risk for aggravation (PNationMS=0.044). The influence of latitude on disability seemed to be lacking in the subgroup of interferon-β treated patients (interaction-PBIONAT=0.042, interaction-PNationMS=0.053). In genetic analyses, for carriers of MC1R:rs1805008(T), who reported increased sensitivity towards sunlight (PNationMS=0.038), the relationship between latitude und the number of GELs was inversed (PNationMS=0.001). Phototherapy induced a vitD and type I interferon signature that was most apparent in the transcriptome of monocytes (P=1×10−6).Conclusion VitD is associated with reduced MS severity and disease aggravation. This is likely driven by sun-exposure, as latitude also correlated with disability and serum vitD. However, sun-exposure might be detrimental for sun-sensitive patients. A direct induction of type I interferons through sun-exposure could explain a reduced effect of latitude in interferon-β treated patients. This could also explain opposite effects of sun-exposure in MS and the type I interferon and sun-sensitivity-associated disease Lupus.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Deutsche Forschungsgemeinschaft (DFG; SFB128 B01 to NS, A10 to KL and HW, Z02 to HW and RH, A09 to HW and CCG), the Interdisziplinaeres Zentrum fuer Klinische Forschung Muenster (IZKF; Wie3/009/16 to HW and NS), and the Ministry of Education and Research (BMBF) [German Competence Network MS (Krankheitsbezogenes Kompetenznetz MS - KKNMS; 01GI1603A to HW and RH, 01GI1601E to HW, LK and CCG, grant no.01GI1601I to CL))]. TFMA was supported by the German Federal Ministry of Education and Research (BMBF) through the Integrated Network IntegraMent, under the auspices of the e:Med Programme (01ZX1614J). French part of this study received funding from the French Ministry of Health (PHRC 2008-005906-38), the EU (BEST-MS, FP7, 305477-2012), and ARSEP (Fondation ARSEP pour la recherche sur la sclerose en plaques) A0-2015 to BP.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the lead ethics committee (Ethik-Kommission der Ruhr-Universitaet Bochum, registration number: 3714-10) and all local committees. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData and R code is available from the authors upon reasonable request. Full results from RNAseq can be found in the supplementary material.